Skip to main content

Table 1 Demographic, disease features and therapy of patients with giant cell arteritis at disease onset and Takayasu arteritis

From: High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins

Variables GCA HC p Variables TA HC p
(n = 18) (n = 16) (n = 29) (n = 29)
Demographic features
Age, years 72.0 (63.7–75.0) 68.5 (63.0–72.0) 0.643 Age, years 38.0 (34.5–48.5) 38.0 (27.5–48.5) 0.392
Females, n (%) 14 (77.8) 11 (68.8) 0.551 Females, n (%) 28 (96.6) 27 (93.1) 0.553
Disease features and therapy
GCA Results TA Results
Headache, n (%) 12 (66.7) Disease duration, months 108 (60–186)
Constitutional symptoms, n (%) 8 (44.4) Angiographic type V, n (%) 16 (55.2)
Cranial ischemic manifestations, n (%) 8 (44.4) Previous ischemic events, n (%) 11 (37.9)
Jaw claudication, n (%) 6 (33.3) Active disease, n (%) 11 (37.9)
Visual symptoms, n (%) 4 (22.2) Remission, n (%) 18 (62.1)
Polymyalgia rheumatica, n (%) 4 (22.2) Statins, n (%) 16 (55.2)
Headache, n (%) 12 (66.7) Prednisone, n (%) 16 (55.2)
ESR, mm/1st hour 69.6 ± 28.7 Prednisone daily dose, mg 8.7 (5.0–28.7)
CRP, mg/l 40.0 (20.2–84.2) Immunosuppressive agents, n (%) 19 (65.5)
Positive TAB, n/total 8/11 Biological agents, n (%) 9 (31.0)
Positive PET-CT scan, n/total 13/15   
  1. Continuous variables are presented as mean ± standard deviation or as median and interquartile range
  2. CRP C-reactive protein, ESR erythrocyte sedimentation rate, GCA giant cell arteritis, HC healthy controls, n number of patients, PET-CT positron emission computed tomography, TA Takayasu arteritis, TAB temporal artery biopsy